Several factors influence how well aspirin works in older adults. In general, effectiveness reflects a balance between preventing clots (benefit) and causing bleeding (risk), which shifts with age. Key factors include:
- Indication and baseline thrombotic risk
- Primary prevention vs secondary prevention: aspirin’s net benefit is smaller for primary prevention in older people because the bleeding risk is higher, whereas in people with prior heart attack or stroke the antiplatelet benefit is more established.
- Bleeding risk (a major counterbalance to effectiveness)
- GI bleeding and ulcers are more common with age.
- Intracranial bleeding risk increases in older adults.
- Additional risk with a history of ulcers, heavy alcohol use, H. pylori infection, and concurrent use of NSAIDs or anticoagulants.
- Concomitant medications and drug interactions
- NSAIDs (e.g., ibuprofen) can diminish aspirin’s antiplatelet effect when taken together.
- Anticoagulants (warfarin, DOACs) or other antiplatelet drugs raise bleeding risk.
- SSRIs/SNRIs and some other drugs can increase GI bleeding risk.
- Proton pump inhibitors can reduce GI bleeding risk, but there are drug interactions to monitor (and some interactions with certain antiplatelet regimens).
- Formulation, absorption, and adherence
- Plain aspirin and some enteric-coated or delayed-release forms may have different absorption in older adults, especially with age-related GI changes.
- Adherence can be a big issue in older people due to cognitive impairment, complex regimens, or swallowing difficulties.
- Dose matters: low-dose aspirin (commonly 75–100 mg daily) is standard for antiplatelet purposes, but formulation and timing can affect consistency of effect.
- Pharmacokinetic and pharmacodynamic changes with aging
- Age-related changes in gastric mucosa and protective barriers increase vulnerability to GI injury.
- Hepatic and renal function decline can affect metabolism and elimination of salicylate, potentially altering bleeding risk and toxicity (even at low doses in some scenarios).
- Platelet biology may change with age (platelet turnover and reactivity), influencing how completely aspirin suppresses platelet aggregation in an individual.
- Comorbidities common in older adults
- Chronic kidney disease, liver disease, diabetes, and inflammatory states can alter hemostasis and platelet function.
- Atrial fibrillation, valvular disease, or other conditions may lead to combined therapies that tilt the risk-benefit balance.
- Individual variability and aspirin resistance
- Some people show “aspirin resistance” or variable response due to high platelet turnover or alternative pathways of platelet activation. This is not fully predictable and is not routinely tested in clinical practice.
- Lifestyle and health status
- Alcohol use, smoking, nutrition, and overall frailty can influence bleeding risk and cardiovascular risk, indirectly affecting aspirin’s net effectiveness.
If you’re considering aspirin therapy in an older person, it’s important to assess both the cardiovascular risk reduction and the bleeding risk, review all other meds, consider GI protection if appropriate, and discuss the plan with a clinician who can tailor the approach to the individual's risks and health status.